Dynavax Technologies Q1 2025 Update
| Field | Detail |
|---|---|
| Company | Dynavax Technologies Corp |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Dynavax Q1 2025 filing shows financial details, focus on common stock & rights. #Dynavax
AI Summary
Dynavax Technologies Corp. reported its first quarter 2025 results, ending March 31, 2025. The company's financial filings indicate a focus on its common stock and preferred share purchase rights. Specific financial figures for revenue and other metrics from Q1 2025 and Q1 2024 are detailed within the report.
Why It Matters
This filing provides insight into Dynavax's financial performance and operational status during the first quarter of 2025, which can influence investor decisions and market perception.
Risk Assessment
Risk Level: medium — The filing contains standard financial reporting for a public company, but the absence of specific revenue or profit figures in the provided snippet necessitates a medium risk assessment.
Key Numbers
- 2.5 — Fiscal Year End (Indicates the company's fiscal year concludes on December 31st.)
- 0.0549058 — Common Stock Shares (Represents shares outstanding for common stock.)
- 0.0955338 — Preferred Share Purchase Rights (Represents preferred share purchase rights.)
Key Players & Entities
- DYNAVAX TECHNOLOGIES CORP (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250506 (date) — Filing Date
- 2025-01-01 (date) — Q1 2025 Start Date
- 2024-01-01 (date) — Q1 2024 Start Date
FAQ
What were Dynavax's total revenues for the first quarter of 2025?
The provided filing snippet does not explicitly state the total revenues for the first quarter of 2025. It indicates the reporting period as 2025-01-01 to 2025-03-31.
How does Dynavax's Q1 2025 revenue compare to Q1 2024?
The filing snippet shows data points for 'us-gaap:ProductMember' and 'dvax:OtherRevenueMember' for both Q1 2025 and Q1 2024, but specific comparative revenue figures are not detailed here.
What is the significance of 'dvax:renewal_term' mentioned in the filing?
The filing mentions 'dvax:renewal_term' with a value of 'utr:D', but its specific financial implication or context is not elaborated in the provided text.
What is the company's primary SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
When was Dynavax Technologies Corp. incorporated?
The state of incorporation for Dynavax Technologies Corp. is Delaware (DE).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding DYNAVAX TECHNOLOGIES CORP.